Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Neurological disease drug developer Axial raised $37.3m from investors including Taiho Ventures while Best Buy is purchasing OSF and Legal & General-backed remote healthcare technology provider Current Health.

Eli Lilly participated in a series B round for the cardiorenal treatment specialist that will support clinical drug trials, boosting its overall funding to $193m.

Legend Holdings and Kawin Technology-backed Sciwind topped up its coffers in a series C round to advance its metabolic disease drug pipeline.

Singtel Innov8 is set to exit cybersecurity technology developer Bitglass in an acquisition deal while Nio Capital contributed to marketing software developer Whale's $50m series B round.

The Duchenne muscular dystrophy drug developer's initial public offering could prove an exit ramp for Roche and Merck & Co.

The Lundbeck, Chiesi Group and Li-Cor Biosciences-backed eye and bladder cancer therapeutics developer has filed to go public on Nasdaq in an offering with a $100m placeholder target.

Mobiliar took part in a $35m round for medicine transportation system developer SkyCell while Nice Investment co-led wealth management software provider Fount's $33.4m series C.

Eli Lilly, Taikang and Tencent are in line to exit the diabetes equipment maker, which has filed to go public in Hong Kong next week.

Itochu, Qualcomm, Hearst, Catholic Health Initiatives, TriZetto and IBM are all set to exit the health plan platform developer.